Shares of Bavarian Nordic (OTCMKTS:BVNRY) took a hit Monday,opening at $8.67 after closing at $9.19. That's a 4.4% drop, with just 228 shares traded.
Stock has been struggling. Its 50-day simple moving average is $9.81, while the 200-day average is $9.92 . Bavarian Nordic has market cap of $2.09 billion, price-to-earnings ratio 11.55,and beta of 1.19 — moderately volatile against broader market.
May 13, company reported latest earnings: EPS of $0.01 for quarter. It showed net margin of 19.74% and return on equity 9.32%. Quarterly revenues hit $165.70 million.
Founded 1994 in Martinsried, Germany,Bavarian Nordic is a biotech player. It develops, manufactures, and sells vaccines and immunotherapies. Its research and manufacturing aim at infectious diseases and cancer .
Its vaccine lineup includes Jynneos™ (also known as Imvamune®/Imvanex®) for smallpox and monkeypox in U.S., EU, Canada. There's also Rabipur® for rabies and Encepur® for tick-borne encephalitis.
Investors are watching. Recent stock dip raises questions on Bavarian Nordic's future path. With market dynamics and financials in play,what's next for the stock?
